Research
Hormonal
Oral semaglutide (7-14 mg/day) provides glucose-lowering and weight-loss effects comparable to subcutaneous formulations, though with lower bioavailability requiring higher doses.
If you prefer pills over injections, oral semaglutide is an option. You must take it on an empty stomach before breakfast, which requires discipline. It uses a higher dose than the shot version to compensate for lower absorption.
GoodQualifiesHIGH confidence
Although oral bioavailability is much lower than by sc injection - hence the much higher dose required (oral 7–14 mg/day versus sc 1–2 mg/week) - tablets do not incur the production requirement of sterile injectable solutions.
Why this rating
FDA approved, discussed in clinical context.
Source
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey et al. · Peptides · 2023
DOI 10.1016/j.peptides.2023.170939
narrative_reviewCited 103×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly subcutaneous administration of GLP-1R/GIPR dual agonist tirzepatide (up to 15 mg/week) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with efficacy exceeding current GLP-1RAs.Good
- Combining the amylin analogue cagrilintide (4.5 mg/week) with semaglutide (2.4 mg/week) results in greater weight loss (15.4% reduction) than either agent alone in obese or overweight individuals.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →